Recursion gets $30M from Roche; Chinese siRNA biotech to go public in Hong Kong news2025-10-29T14:32:31+00:00October 29th, 2025|Endpoints News|
Regeneron discloses CRL; AbbVie stops work on Dragonfly assetnews2025-10-28T14:37:24+00:00October 28th, 2025|Endpoints News|
FDA approves Syndax’s menin inhibitor with black-box warning; GSK’s ADC dealnews2025-10-27T15:13:54+00:00October 27th, 2025|Endpoints News|
FDA rejects Sydnexis’ myopia drug for kids; Chugai to buy Renalys for $98M upfrontnews2025-10-24T15:08:08+00:00October 24th, 2025|Endpoints News|
A trio of biotechs target $250M offerings; Regeneron stops cell therapy trialnews2025-10-22T15:08:19+00:00October 22nd, 2025|Endpoints News|
Neuphoria scraps social anxiety drug; Minerva doubles down on schizophrenia therapynews2025-10-21T15:03:33+00:00October 21st, 2025|Endpoints News|
Celcuity’s shares rally after ESMO readouts; Disc Medicine’s $220M stock salenews2025-10-20T15:24:27+00:00October 20th, 2025|Endpoints News|
Kezar seeks strategic alternatives after FDA setback; Taysha, Astellas’ Rett syndrome agreement expiresnews2025-10-17T14:07:20+00:00October 17th, 2025|Endpoints News|
Dianthus inks licensing deal with Chinese biotech; C4 targets $125M offeringnews2025-10-16T14:32:04+00:00October 16th, 2025|Endpoints News|
Boehringer makes an ADC deal with AimedBio; EyePoint’s $150M stock salenews2025-10-15T14:38:15+00:00October 15th, 2025|Endpoints News|
